Neil L. Spector

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Wenle Xia, Robert J. Mullin, Barry R. Keith et al. · Oncogene · 2002 · 669 citations

Medicine, Oncology, Pharmacology +16

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2005 · 625 citations · Full text

Medicine, Oncology, Pharmacology +17

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

Wenle Xia, Sarah Bacus, Priti S. Hegde et al. · Proceedings of the National Academy of Sciences · 2006 · 377 citations · Full text

Medicine, Oncology, Pharmacology +17

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Neil L. Spector, Wenle Xia, Howard A. Burris et al. · Journal of Clinical Oncology · 2005 · 365 citations · Full text

Medicine, Oncology, Pharmacology +17

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

Takuya Osada, Gabriel T. Chong, Robert L. Tansik et al. · Cancer Immunology Immunotherapy · 2008 · 310 citations · Full text

Medicine, Immunology, Oncology +17